Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

22.81 USD -0.17 (-0.74%)
Streaming Delayed Price Updated: 1:31 PM EDT, Jun 14, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 324,563
Open 23.09
Bid (Size) 22.81 (2)
Ask (Size) 22.82 (5)
Prev. Close 22.98
Today's Range 22.80 - 23.34
52wk Range 18.18 - 27.35
Shares Outstanding 313,387,205
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
Exelixis, Inc. (Nasdaq: EXEL) today announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE: BMY) for STELLAR-002, a new phase 1b trial evaluating XL092 in... 
From Business Wire News Releases
Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Prese
Regulatory News: 
From Business Wire News Releases

Performance

YTD
+11.11%
+11.11%
1 Month
-10.76%
-10.76%
3 Month
-5.63%
-5.63%
6 Month
+10.94%
+10.94%
1 Year
+0.04%
+0.04%

More News

Read More
Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Prese
From Business Wire News Releases
Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021
From Business Wire News Releases
Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Pati
From Business Wire News Releases
Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Prev
From Business Wire News Releases
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
From Business Wire News Releases
Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
From Business Wire News Releases
Here's What Crushed Exelixis' Earnings
Tags Market News EXEL BMY
From Motley Fool
2 Top Biotech Stocks to Buy Right Now
Tags HGEN Market News EXEL
From Motley Fool
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients
Tags News Market News Briefs
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.